Search results for "MESH: Middle Aged"

showing 10 items of 66 documents

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]

2006

International audience; The definition of appropriate use of drugs is questioned in oncology. Daily therapeutic practices were compared to official labelling and to published scientific data in this retrospective study. It was carried out in two respective specialised centers, from January to September 2004. All chemotherapies administered for adult solid tumours and including one of the eleven studied drugs were evaluated. The analysis of use was performed by drug : conformity to the validated labelling and level of scientific evidence (at the period study). The study included 1,561 drug uses in 1,211 patients. The overall rate of conformity to official labelling was 81.7 % (67.1 % of stri…

AdultMaleAdolescentMESH : Retrospective StudiesMESH : MaleMESH: Drug LabelingMESH : AgedAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerMESH : BenchmarkingMESH : Drug LabelingMESH: Aged 80 and overMESH: Practice Guidelines as TopicMESH: Benchmarking[SDV.CAN] Life Sciences [q-bio]/CancerNeoplasmsMESH : AdolescentHumansMESH: NeoplasmsMESH : Middle AgedMESH : FemaleMESH : Aged 80 and overAgedDrug LabelingRetrospective StudiesAged 80 and overMESH: AdolescentMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansMESH: AdultMESH: Retrospective StudiesMiddle AgedMESH : AdultMESH : NeoplasmsMESH: MaleBenchmarkingMESH : Practice Guidelines as TopicMESH : Antineoplastic AgentsPractice Guidelines as TopicMESH: Antineoplastic AgentsFemaleMESH: Female
researchProduct

[Investigation of an outbreak of norovirus gastroenteritis in a geriatric hospital]

2005

National audience; In aged-care facilities, gastroenteritis outbreaks are responsible for big trouble in the management of cares to the elderly. In November 2002, a gastroenteritis outbreak was observed in 5 of the 6 wards of the geriatric hospital La Charité, University Hospital of Saint-Etienne, France, with an attack rate of 38.5% in the elderly (70 infected from 182 patients) and of 26.0% in the nursing staff (40 infected from 154 agents). The outbreak lasted 30 days with a peak corresponding to 79.8% of the cases between the 11(th) and the 20(th) of November. The first cases were observed in the two short-term-care wards; then, the outbreak spread rapidly to 3 of the 4 long-term care u…

AdultMaleMESH: NorovirusMESH : MaleMESH : Hospitals SpecialMESH : AgedMESH: GeriatricsHospitals Special[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyDisease OutbreaksMESH: Aged 80 and overHumansMESH : Middle AgedMESH : Disease OutbreaksMESH : FemaleMESH: Disease OutbreaksMESH : Aged 80 and overMESH : GeriatricsMESH: Caliciviridae InfectionsAgedCaliciviridae InfectionsAged 80 and overMESH: Aged[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Middle AgedMESH: HumansMESH : NorovirusNorovirusMESH : HumansMESH: Hospitals SpecialMESH: AdultMiddle AgedMESH : AdultMESH: MaleMESH: GastroenteritisGastroenteritisMESH : GastroenteritisGeriatrics[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyFemaleMESH : Caliciviridae InfectionsMESH: Female
researchProduct

TP53 codon 72 polymorphism and cervical cancer

2009

Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different st…

ArginineMESH : Polymorphism GeneticMESH: Genes p53MESH : AgedPhysiologyUterine Cervical NeoplasmsMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineGenotypeMESH : FemaleCervical cancerGeneticsMESH: AgedMESH : Papillomavirus Infections0303 health sciencesMESH: Middle AgedHPV infectionMESH: Genetic Predisposition to DiseaseMiddle AgedMESH : AdultWILD-TYPE P53Hardy–Weinberg principle3. Good healthMESH: Uterine Cervical NeoplasmsOncologyMESH: Young Adult030220 oncology & carcinogenesisMeta-analysisFemaleAdultAdolescentMESH : Uterine Cervical NeoplasmsMESH : Young Adult[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Genes p5303 medical and health sciencesYoung AdultSQUAMOUS INTRAEPITHELIAL LESIONSMESH : AdolescentINDIAN WOMENMESH: Polymorphism GeneticmedicineHumansGenetic Predisposition to DiseaseMESH : Middle AgedAllele030304 developmental biologyAgedMESH: AdolescentMESH: HumansPolymorphism GeneticHUMAN-PAPILLOMAVIRUS TYPE-16business.industryP53 ARG72PRO POLYMORPHISMHEALTHY WOMENPapillomavirus InfectionsMESH : HumansMESH: AdultOdds ratiomedicine.diseaseGenes p53GENOTYPESHARDY-WEINBERG EQUILIBRIUMRISK-FACTORSMESH : Genetic Predisposition to DiseasebusinessMESH: FemaleHPV INFECTIONLancet Oncology
researchProduct

Obesity interferes with the orosensory detection of long-chain fatty acids in humans

2014

Background: The association between the orosensory detection of lipids, preference for fatty foods, and body mass index (BMI; in kg/m 2 ) is controversial in humans. Objective: We explored the oral lipid-sensing system and the orosensory-induced autonomic reflex system in lean and obese subjects. Design: Lean (BMI: 19 to ,25; n = 30) and obese (BMI .30; n = 29) age-matched men were enrolled. Their oral threshold sensitivity to linoleic acid (LA) was determined by using a 3-alternative forced-choice ascending procedure, and their eating habits were established by the analysis of 4 consecutive 24-h food-consumption diaries. The effect of brief oral lipid stimulations on plasma triglyceride [(…

Blood GlucoseMaleobesityChemical PhenomenaMESH : Insulin[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionCholesterol VLDLMedicine (miscellaneous)MESH: Food HabitsStimulationMESH: Energy IntakeMESH : TasteMESH : FastingBody Mass Indexchemistry.chemical_compoundMESH: Cholesterol VLDLMESH: Diet RecordsInsulinMESH: ObesityMESH : Physicochemical PhenomenaCompletely randomized designMESH : Food HabitsCross-Over StudiesMESH: Middle AgedMESH : Food PreferencesNutrition and DieteticsFastingMiddle AgedDiet RecordsMESH : TriglyceridesSensory ThresholdsTasteMESH : ObesityMESH: Triglyceridesmedicine.medical_specialtyMESH : MaleLinoleic acidMESH: FastingMESH: InsulinMESH: Cross-Over StudiesMESH: Body Mass IndexLinoleic AcidMESH : Diet RecordsFood PreferencesBMIMESH : Linoleic AcidInternal medicineAutonomic reflexmedicineHumansMESH : Middle AgedhumanMESH: Food PreferencesTriglyceridesMESH : Cholesterol VLDLMESH: Linoleic AcidMESH: HumansCholesterolbusiness.industryMESH : HumansMESH : Energy IntakeFeeding BehaviorMESH : Blood GlucoseMESH : Cross-Over Studiesmedicine.diseaseCrossover studyObesityMESH: Malefat taste[SDV.AEN] Life Sciences [q-bio]/Food and NutritionMESH: Physicochemical PhenomenaMESH : Body Mass IndexEndocrinologychemistryMESH: Blood GlucoseMESH: Tastefood preferenceMESH: Sensory ThresholdsEnergy Intakebusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass indexMESH : Sensory ThresholdsThe American Journal of Clinical Nutrition
researchProduct

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countr…

2015

Summary Background The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age–sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic develo…

GerontologyMaleCHANGING RELATIONNutrition and DiseaseMESH : Life ExpectancyMESH : AgedECONOMIC-DEVELOPMENTPoison controlMESH: Global HealthGlobal HealthSocioeconomic FactorCommunicable DiseaseMESH : Chronic DiseaseHealth TransitionVoeding en ZiekteQuality-Adjusted Life YearSELF-RATED HEALTHMESH : Socioeconomic FactorsMedicineMESH : FemaleMESH: Mortality Premature2. Zero hungerMESH: Agededucation.field_of_studyMESH: Middle AgedMortality rateMedicine (all)GBD2013 diseases[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieGeneral MedicineMiddle Aged3. Good healthMESH : Wounds and InjuriesEpidemiological transitionMESH: Quality-Adjusted Life YearsMESH: Communicable DiseasesNONCOMMUNICABLE DISEASESFemaleQuality-Adjusted Life YearsMESH: Life ExpectancyMESH: Health TransitionHumanMESH: Socioeconomic FactorsACUTE MYOCARDIAL-INFARCTIONMESH : MaleMORTALITY TRENDSPopulationMESH : Health TransitionCommunicable DiseasesArticleLife ExpectancyEUROPEAN-UNIONSDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDisability-adjusted life yearHumansLife ScienceMESH : Middle AgedMortalityeducationPrematureMESH : Mortality PrematureVLAGAgedMESH: Humansbusiness.industryMortality PrematureMESH: Chronic DiseaseMESH : Communicable DiseasesWounds and InjurieMESH : HumansMESH : Quality-Adjusted Life YearsNon-communicable diseaseAged; Chronic Disease; Communicable Diseases; Female; Global Health; Humans; Male; Middle Aged; Mortality Premature; Quality-Adjusted Life Years; Socioeconomic Factors; Wounds and Injuries; Health Transition; Life Expectancy; Medicine (all)medicine.diseaseMESH: MaleLOW SOCIOECONOMIC-STATUSYears of potential life lostSocioeconomic Factors[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesChronic DiseaseLife expectancyRISK-FACTORSMESH : Global HealthWounds and Injuries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessMESH: FemaleDemographyLancet
researchProduct

Very preterm birth: who has access to antenatal corticosteroid therapy?

2010

International audience; We describe the administration of antenatal corticosteroid therapy (ACT) for liveborn very preterm neonates in a population-based study. A total of 790 very preterm neonates (between 24 and 31 full weeks of gestation) were included in this regionally defined population of very preterm neonates in France. The main outcome measure was non-access to ACT. Data were analysed using logistic and polytomous models to control for neonatal and sociodemographic characteristics, mechanisms of very preterm birth and neonatal network organisation. As compared with level III, births in levels I-II maternity units were closely related to non-access to ACT (60.1% vs. 8.8%), but not t…

Gestational hypertensionPediatricsEpidemiologyMESH: Logistic ModelsHealth Services AccessibilityInfant Newborn Diseases[ SDV.CAN ] Life Sciences [q-bio]/CancerCohort Studies0302 clinical medicineMESH: PregnancyMESH : Health Services AccessibilityMESH: Risk FactorsAdrenal Cortex HormonesPregnancyRisk FactorsMESH: Maternal Health ServicesMESH : Socioeconomic FactorsMedicineChildbirthRupture of membranesMESH : FemaleMESH: Cohort StudiesMESH : Infant Newborn Diseaseseducation.field_of_studyMESH: Health Services Accessibility030219 obstetrics & reproductive medicineMESH: Middle AgedObstetricsMESH: Infant NewbornSmokingAge FactorsMiddle AgedMESH : AdultMESH : Risk Factors3. Good healthMESH : SmokingMESH : Infant PrematureMESH: Young AdultGestationFemaleFranceInfant PrematureMESH: Infant PrematureAdultmedicine.medical_specialtyMESH: SmokingMESH: Socioeconomic FactorsReferralAdolescentPopulationMESH : Young AdultMESH : Cohort StudiesMESH: Infant Newborn Diseases[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Infant NewbornMESH: Adrenal Cortex HormonesMESH : Adrenal Cortex Hormones03 medical and health sciencesYoung Adult030225 pediatricsMESH : AdolescentVery Preterm BirthHumansMaternal Health ServicesMESH : Middle AgededucationMESH : FranceMESH: AdolescentMESH: Age FactorsPregnancyMESH: Humansbusiness.industryMESH : HumansInfant NewbornMESH: Adultmedicine.diseaseMESH: FranceMESH : PregnancyLogistic ModelsSocioeconomic FactorsPediatrics Perinatology and Child HealthMESH : Age FactorsbusinessMESH: FemaleMESH : Maternal Health ServicesMESH : Logistic Models
researchProduct

Dioxin emissions and soft-tissue sarcoma: results of a population-based case-control study.

2004

International audience; BACKGROUND: In 1998, the French Ministry of Environment revealed that of 71 French municipal solid waste incinerators processing more than 6 metric tons of material per hour, dioxin emission from 15 of them was above the 10 ng international toxic equivalency factor/m3 (including Besançon, emitting 16.3 ng international toxic equivalency factor/m3) which is substantially higher than the 0.1 international toxic equivalency factor/m3 prescribed by a European directive of 1994. In 2000, a macrospatial epidemiological study undertaken in the administrative district of Doubs, identified two significant clusters of soft-tissue sarcoma and non Hodgkin lymphoma in the vicinit…

MESH : Case-Control StudiesMESH : MaleMESH: Environmental ExposureMESH : AgedMESH : Child PreschoolMESH : Infant NewbornMESH : SarcomaMESH : DioxinsMESH : ChildMESH: Risk FactorsMESH: ChildMESH : AdolescentMESH: IncinerationMESH : Middle AgedMESH : FemaleMESH : Data Interpretation StatisticalMESH : FranceMESH : IncinerationMESH: AgedMESH: AdolescentMESH: HumansMESH: Middle AgedMESH: DioxinsMESH: Infant NewbornMESH: Child PreschoolMESH : HumansMESH: AdultMESH : Infant[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH : AdultMESH: InfantMESH: Case-Control StudiesMESH : Risk FactorsMESH: MaleMESH: France[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Sarcoma[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Data Interpretation StatisticalMESH: FemaleMESH : Soft Tissue NeoplasmsMESH : Environmental ExposureMESH: Soft Tissue Neoplasms
researchProduct